NO20020837L - Fremgangsmåte for å identifisere et stoffs egenskaper hensyn til humane prostaglandin D-reseptorer - Google Patents

Fremgangsmåte for å identifisere et stoffs egenskaper hensyn til humane prostaglandin D-reseptorer

Info

Publication number
NO20020837L
NO20020837L NO20020837A NO20020837A NO20020837L NO 20020837 L NO20020837 L NO 20020837L NO 20020837 A NO20020837 A NO 20020837A NO 20020837 A NO20020837 A NO 20020837A NO 20020837 L NO20020837 L NO 20020837L
Authority
NO
Norway
Prior art keywords
identifying
substance
human prostaglandin
respect
properties
Prior art date
Application number
NO20020837A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020837D0 (no
Inventor
Hiroyuki Hirai
Kazuyuki Ogawa
Kinya Nagata
Syoichi Takano
Original Assignee
Bml Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bml Inc filed Critical Bml Inc
Publication of NO20020837D0 publication Critical patent/NO20020837D0/no
Publication of NO20020837L publication Critical patent/NO20020837L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
NO20020837A 1999-08-23 2002-02-20 Fremgangsmåte for å identifisere et stoffs egenskaper hensyn til humane prostaglandin D-reseptorer NO20020837L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP23620799 1999-08-23
JP2000153172 2000-05-24
PCT/JP2000/005615 WO2001014882A1 (fr) 1999-08-23 2000-08-22 Identification des proprietes d'une substance pour les recepteurs de prostaglandine d

Publications (2)

Publication Number Publication Date
NO20020837D0 NO20020837D0 (no) 2002-02-20
NO20020837L true NO20020837L (no) 2002-04-22

Family

ID=26532542

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020837A NO20020837L (no) 1999-08-23 2002-02-20 Fremgangsmåte for å identifisere et stoffs egenskaper hensyn til humane prostaglandin D-reseptorer

Country Status (9)

Country Link
US (1) US6884593B1 (de)
EP (1) EP1211513B1 (de)
JP (1) JP3486408B2 (de)
AT (1) ATE315230T1 (de)
AU (1) AU772121B2 (de)
CA (1) CA2383135C (de)
DE (2) DE60025368T2 (de)
NO (1) NO20020837L (de)
WO (1) WO2001014882A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
JP2005508164A (ja) * 2001-10-10 2005-03-31 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ２１１３２、ヒトｇタンパク質共役レセプターファミリーメンバーおよびそれらの使用
WO2003097598A1 (en) * 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
WO2003097042A1 (en) * 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Pgd2 receptor antagonist
NZ541234A (en) 2002-12-20 2008-06-30 Amgen Inc Asthma and allergic inflammation modulators
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US7714132B2 (en) 2004-03-11 2010-05-11 Actelion Pharmaceuticals, Ltd. Tetrahydropyridoindole derivatives
CA2563707A1 (en) * 2004-04-20 2005-11-03 Pfizer Inc. Method of treating neuropathic pain using a crth2 receptor antagonsit
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
ATE517085T1 (de) 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007039736A1 (en) * 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
WO2008012511A1 (en) 2006-07-22 2008-01-31 Oxagen Limited Compounds having crth2 antagonist activity
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
WO2009061681A2 (en) * 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc Antagonists of pgd2 receptors
WO2009061676A2 (en) * 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
WO2009085177A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Phenyl acetic acid derivatives as inflammation modulators
RS53142B (sr) 2008-01-18 2014-06-30 Atopix Therapeutics Limited Jedinjenja koja imaju antagonističku aktivnost na crth2
US8168673B2 (en) 2008-01-22 2012-05-01 Oxagen Limited Compounds having CRTH2 antagonist activity
UA98839C2 (en) * 2008-02-01 2012-06-25 Панмира Фармасьютикалз, Ллк. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CA2713139C (en) 2008-02-01 2013-04-23 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
EP2257536A4 (de) * 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc Cyclische diarylether als antagonisten von prostaglandin-d2-rezeptoren
EP2245022A4 (de) * 2008-02-25 2012-02-22 Panmira Pharmaceuticals Llc Antagonisten von prostaglandin-d2-rezeptoren
US8426449B2 (en) * 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
CA2729292C (en) 2008-07-03 2013-09-03 Amira Pharmaceuticals, Inc. Phenoxyphenyl sulfide, sulfinyl and sulfonyl antagonists of prostaglandin d2 receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
US20100173313A1 (en) * 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
WO2011014587A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
CN102596902A (zh) * 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
JP2013516475A (ja) 2010-01-06 2013-05-13 アミラ ファーマシューティカルズ，インク． Ｄｐ２アンタゴニストおよびその使用
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
WO2014066568A1 (en) 2012-10-24 2014-05-01 Winthrop-University Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
EP4070113A4 (de) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Beurteilung von präeklampsie unter verwendung von tests für freien und dissoziierten plazentalen wachstumsfaktor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69734141T2 (de) * 1996-06-05 2006-07-13 Bml Inc. PROTEIN, DAS FÜR MENSCHLICHE Th2-ZELLEN SPEZIFISCH IST, DAFÜR KODIERENDES GEN UND KORRESPONDIERENDE TRANSFORMANTE, REKOMBINANTER VEKTOR UND MONOKLONALER ANTKÖRPER
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2

Also Published As

Publication number Publication date
DE60025368T2 (de) 2006-09-14
CA2383135C (en) 2010-11-30
EP1211513B1 (de) 2006-01-04
ATE315230T1 (de) 2006-02-15
AU6598800A (en) 2001-03-19
DE60025368D1 (de) 2006-03-30
JP3486408B2 (ja) 2004-01-13
AU772121B2 (en) 2004-04-08
WO2001014882A1 (fr) 2001-03-01
EP1211513A4 (de) 2003-04-16
US6884593B1 (en) 2005-04-26
CA2383135A1 (en) 2001-03-01
DE1211513T1 (de) 2002-11-14
EP1211513A1 (de) 2002-06-05
NO20020837D0 (no) 2002-02-20

Similar Documents

Publication Publication Date Title
NO20020837D0 (no) Fremgangsmåte til å identifisere egenskaper til stoff som påvirker prostaglandin D reseptorer
DE69938662D1 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
NO983431L (no) Anti-klöemidler
PT1235787E (pt) Receptores agonistas beta2 adrenergicos
DE60328870D1 (de) Verfahren zur modulierung von cd200-rezeptoren
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
DK0841928T3 (da) Sustained release-formulering af d-threo-methylphenidat
DE69829293D1 (de) Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen
NO20010446L (no) Substituert anilidforbindelser og metoder
NO980172D0 (no) Löselige reseptorer og ligandantistoffer for behandling av immunologisk sykdom
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
HUT77631A (hu) Eljárás a levobupivakain és származékai rezolválására
ATE210984T1 (de) Verwendung von serotonin- und dopaminrezeptorblockern zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
ES2162936T3 (es) Tratamiento de la ansiedad.
ATE432350T1 (de) G-protein gekoppelte rezeptoren
BG102064A (en) Method for increasing the retinal blood circulation
ATE254122T1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
ATE203659T1 (de) Vorrichtung zum transport eines knochensegments zur überbrückung eines knochendefekts
BR0012921A (pt) Compostos calcilìticos
ES2104509B1 (es) Nuevos compuestos derivados de 2-(3,4-disustituido-1-piperazinil)-5-fluoropirimidina.
EA199700297A1 (ru) Новый способ борьбы с насекомыми
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
ITMI950956A0 (it) Uso degli enantiomeri (s) di derivati 1,4-diidropiridinici per il trattamento dell'insufficienza cardiaca